{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:17:04Z","timestamp":1794374224334,"version":"4.9.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.immuni.2026.10.005","type":"journal-article","created":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:00:50Z","timestamp":1794326450000},"page":"3061-3080.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["TIGIT and PD-L1 co-blockade promotes dendritic cell-dependent production of non-exhausted CD8+ T cells"],"prefix":"10.1016","volume":"59","author":[{"given":"Ellen","family":"Duong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Foo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl L.","family":"Banta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Nutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya A.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine B.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-9598","authenticated-orcid":false,"given":"Alan","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Chestnut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille-Charlotte","family":"Balan\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Tomaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017daneta","family":"Andrusivov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1113-6128","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Decalf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8554-167X","authenticated-orcid":false,"given":"Shiuh-Ming","family":"Luoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4147-0215","authenticated-orcid":false,"given":"Sandra","family":"Rost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-9264","authenticated-orcid":false,"given":"Lisa M.","family":"McGinnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6741-3702","authenticated-orcid":false,"given":"Milena","family":"Hornburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene Y.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-9712","authenticated-orcid":false,"given":"Soyoung A.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6132-7299","authenticated-orcid":false,"given":"Ira","family":"Mellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2026.10.005_bib1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41590-021-00949-7","article-title":"Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity","volume":"22","author":"Collier","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8(+) T Cell Effector Function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.10.005_bib5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","article-title":"TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating costimulation","volume":"5","author":"Nutsch","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.immuni.2026.10.005_bib6","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.immuni.2026.10.005_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/d41573-026-00031-7","article-title":"TIGIT's immuno-oncology teachings","volume":"25","author":"Mullard","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.immuni.2026.10.005_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","article-title":"An intra-tumoral niche maintains and differentiates stem-like CD8 T cells","volume":"576","author":"Jansen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.10.005_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","article-title":"CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor","volume":"56","author":"Prokhnevska","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib11","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.10.005_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai8593","article-title":"The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness","volume":"1","author":"Wu","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.10.005_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.10.005_bib16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.10.005_bib17","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41590-019-0403-4","article-title":"Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection","volume":"20","author":"Yao","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","article-title":"Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1\u2212CD8+ Tumor-Infiltrating T Cells","volume":"50","author":"Kurtulus","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adg0878","article-title":"Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1+ PD-1+ CD8 T cells","volume":"8","author":"Humblin","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib22","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1\u2013targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.10.005_bib23","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.10.005_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo4997","article-title":"Advancing beyond the twists and turns of T cell exhaustion in cancer","volume":"14","author":"van der Heide","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib25","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004711","article-title":"TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy","volume":"10","author":"Chiang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.immuni.2026.10.005_bib27","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib29","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.20130573","article-title":"Activating Fc \u03b3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies","volume":"210","author":"Bulliard","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","article-title":"Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells","volume":"1","author":"Selby","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2026.10.005_bib31","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s43018-022-00447-1","article-title":"Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc\u03b3R engagement and type I interferon signaling","volume":"3","author":"Yofe","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.immuni.2026.10.005_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic Cells and Cancer Immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib35","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.immuni.2023.08.014","article-title":"Dendritic cells as shepherds of T cell immunity in cancer","volume":"56","author":"Pittet","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib36","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","article-title":"PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer","volume":"1","author":"Oh","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.immuni.2026.10.005_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18570-x","article-title":"PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade","volume":"11","author":"Peng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2026.10.005_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114141","article-title":"Batf3+ DCs and the 4-1BB\/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1\/PD-L1 blockade efficacy","volume":"43","author":"Ziblat","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.immuni.2026.10.005_bib40","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s43018-024-00734-z","article-title":"Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols","volume":"5","author":"Barboy","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.immuni.2026.10.005_bib41","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib42","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.10.005_bib43","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.10.005_bib44","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib47","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cell.2013.07.014","article-title":"Genetic Tracing via DNGR-1 Expression History Defines Dendritic Cells as a Hematopoietic Lineage","volume":"154","author":"Schraml","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.immuni.2016.10.010","article-title":"Functions of Murine Dendritic Cells","volume":"45","author":"Durai","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib49","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1128\/jvi.68.2.897-904.1994","article-title":"An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR\/Gross MuLV cytotoxic T lymphocytes","volume":"68","author":"White","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.immuni.2026.10.005_bib50","first-page":"7920","article-title":"Immunization against endogenous retroviral tumor-associated antigens","volume":"61","author":"Kershaw","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2026.10.005_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.10.005_bib52","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.immuni.2019.03.009","article-title":"Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species","volume":"50","author":"Zilionis","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib53","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200264","article-title":"Tumor-infiltrating dendritic cell states are conserved across solid human cancers","volume":"218","author":"Gerhard","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.immuni.2016.08.015","article-title":"Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species","volume":"45","author":"Guilliams","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib55","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib56","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.immuni.2009.08.027","article-title":"Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells","volume":"31","author":"Dorner","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib57","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1084\/jem.20100223","article-title":"The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells","volume":"207","author":"Crozat","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib58","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.4049\/jimmunol.1101717","article-title":"Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8\u03b1+ type","volume":"187","author":"Crozat","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00035","article-title":"Mouse Conventional Dendritic Cells Can be Universally Classified Based on the Mutually Exclusive Expression of XCR1 and SIRP\u03b1","volume":"6","author":"Gurka","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib60","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jaci.2018.11.045","article-title":"A case of mistaken identity: The MAR-1 antibody to mouse Fc\u03b5RI\u03b1 cross-reacts with Fc\u03b3RI and Fc\u03b3RIV","volume":"143","author":"Tang","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib61","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical Role for CD103(+)\/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib62","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1084\/jem.20030448","article-title":"Regulation of Dendritic Cell Migration to the Draining Lymph Node: Impact on T Lymphocyte Traffic and Priming","volume":"198","author":"Mart\u00edn-Fontecha","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib63","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N","article-title":"Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation","volume":"28","author":"Sallusto","year":"1998","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib64","article-title":"Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity","volume":"15","author":"Lee","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.immuni.2026.10.005_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082237","article-title":"Bright fluorescence monitoring system utilizing Zoanthus sp. green fluorescent protein (ZsGreen) for human G-protein-coupled receptor signaling in microbial yeast cells","volume":"8","author":"Nakamura","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.immuni.2026.10.005_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1247\/csf.07011","article-title":"GFP-like Proteins Stably Accumulate in Lysosomes","volume":"33","author":"Katayama","year":"2008","journal-title":"Cell Struct. Funct."},{"key":"10.1016\/j.immuni.2026.10.005_bib67","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240152","article-title":"Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer","volume":"221","author":"Tsimberidou","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib68","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","article-title":"The TIGIT\/CD226 Axis Regulates Human T Cell Function","volume":"188","author":"Lozano","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib70","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.immuni.2020.09.006","article-title":"Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy","volume":"53","author":"Weulersse","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib71","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.immuni.2020.04.005","article-title":"Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection","volume":"52","author":"Bosteels","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib72","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2205983119","article-title":"Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies","volume":"119","author":"Lutz","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.10.005_bib73","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Shapir Itai","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib74","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood.V99.9.3263","article-title":"Type I interferons produced by dendritic cells promote their phenotypic and functional activation","volume":"99","author":"Montoya","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2026.10.005_bib75","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.4049\/jimmunol.1101313","article-title":"Type I IFN Drives a Distinctive Dendritic Cell Maturation Phenotype That Allows Continued Class II MHC Synthesis and Antigen Processing","volume":"188","author":"Simmons","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib76","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic Cells: Specialized and Regulated Antigen Processing Machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib77","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1073\/pnas.0910609107","article-title":"Mature dendritic cells use endocytic receptors to capture and present antigens","volume":"107","author":"Platt","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.10.005_bib78","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1535-7163.MCT-20-0464","article-title":"Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies","volume":"20","author":"Preillon","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.immuni.2026.10.005_bib79","article-title":"Effective Anti-tumor Response by TIGIT Blockade Associated With Fc\u03b3R Engagement and Myeloid Cell Activation","volume":"11","author":"Han","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib80","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1158\/0008-5472.CAN-23-2455","article-title":"Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells","volume":"84","author":"Piovesan","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2026.10.005_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw0902","article-title":"CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells","volume":"4","author":"Ovcinnikovs","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib82","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2026.10.005_bib83","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","article-title":"CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity","volume":"56","author":"Moreno Ayala","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib84","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.immuni.2023.01.010","article-title":"Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer","volume":"56","author":"Zagorulya","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.10.005_bib85","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ccell.2024.06.014","article-title":"Lymphatic-localized Treg-mregDC crosstalk limits antigen trafficking and restrains anti-tumor immunity","volume":"42","author":"You","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nm0697-625","article-title":"Flt3 ligand induces tumor regression and antitumor immune responses in vivo","volume":"3","author":"Lynch","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071525","article-title":"The Flt3L\/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy","volume":"13","author":"Cueto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.immuni.2026.10.005_bib88","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties of mouse and human IgG receptors and their contribution to disease models","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2026.10.005_bib89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12350","article-title":"Mouse and human FcR effector functions","volume":"268","author":"Bruhns","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.immuni.2026.10.005_bib90","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib91","first-page":"43","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"Qiu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.immuni.2026.10.005_bib92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2023.12.013","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/science.adf1329","article-title":"Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients","volume":"384","author":"Mathew","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.10.005_bib94","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib95","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib96","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1016\/j.cell.2024.07.018","article-title":"LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity","volume":"187","author":"Ngiow","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.10.005_bib97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2026.10.005_bib98","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.immuni.2026.10.005_bib99","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11912-023-01406-4","article-title":"The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma","volume":"25","author":"Albrecht","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.immuni.2026.10.005_bib100","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.immuni.2026.10.005_bib101","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","article-title":"CellChat for systematic analysis of cell\u2013cell communication from single-cell transcriptomics","volume":"20","author":"Jin","year":"2025","journal-title":"Nat. Protoc."}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761326004310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761326004310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:30:03Z","timestamp":1794328203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761326004310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1074761326004310"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2026.10.005","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIGIT and PD-L1 co-blockade promotes dendritic cell-dependent production of non-exhausted CD8+ T cells","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2026.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}